FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffrey Tyner

Research Profile

Chemicals & Drugs

Living Beings

Mouse

Anatomy

Physiology

Phenomena

Phosphorylation

Disorders

Co-author Network

Publications

TOP 3
Julia E Maxson; Shannon McWeeney; Stephen T Oh; Daniel A Pollyea; J Blake Pond; Cristina E Tognon; Beth Wilmot; Anupriya Agarwal; Daniel Bottomly; Bill Hoon Chang; Robert H Collins; Michael W N Deininger; Brian J Druker; Christopher A Eide; Angela G Fleischman; Jason Gotlib; Basem Goueli; Marc Loriaux; Jeffrey W Tyner
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Erin B Dickerson; Brian J Druker; Wade Edris; Marc Loriaux; Valerie Macdonald; Kevin Marley; Vidya Schalk; Jeffrey W Tyner; Stuart C Helfand
Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.
Daniel Bottomly; Brian J Druker; Christopher A Eide; Marc Loriaux; Jeffrey W Tyner; Beth Wilmot; Shannon McWeeney
HitWalker: variant prioritization for personalized functional cancer genomics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffrey Tyner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Julia E Maxson; Shannon McWeeney; Stephen T Oh; Daniel A Pollyea; J Blake Pond; Cristina E Tognon; Beth Wilmot; Anupriya Agarwal; Daniel Bottomly; Bill Hoon Chang; Robert H Collins; Michael W N Deininger; Brian J Druker; Christopher A Eide; Angela G Fleischman; Jason Gotlib; Basem Goueli; Marc Loriaux; Jeffrey W Tyner
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
The New England journal of medicine 2013;368(19):1781-90.
2013: Erin B Dickerson; Brian J Druker; Wade Edris; Marc Loriaux; Valerie Macdonald; Kevin Marley; Vidya Schalk; Jeffrey W Tyner; Stuart C Helfand
Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.
Translational oncology 2013;6(2):158-68.
2013: Daniel Bottomly; Brian J Druker; Christopher A Eide; Marc Loriaux; Jeffrey W Tyner; Beth Wilmot; Shannon McWeeney
HitWalker: variant prioritization for personalized functional cancer genomics.
Bioinformatics (Oxford, England) 2013;29(4):509-10.
2013: Stephen E Spurgeon; Jeffrey W Tyner; Yvonne Pak; Anjali Pandey; Uma Sinha; Dale Baker; Andreas Betz; Russell Burke; Greg Coffey; Francis DeGuzman; Brian J Druker; Luke B Fletcher; Stanley J Hollenbach; Marc Loriaux
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
The Journal of pharmacology and experimental therapeutics 2013;344(2):378-87.
2013: Molly F Kulesz-Martin; James Lagowski; Susan Olson; Christopher Ryan; George Thomas; Toni West; Aaron Wortham; Jeffrey W Tyner
A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.
Cancer biology & therapy 2013;14(2):95-9.
2013: Jeffrey W Tyner; Marry M van den Heuvel-Eibrink; Wayne F Yang; Christian Michel Zwaan; Stephen T Oh; Thomas O'Hare; Stephen E Spurgeon; Armand Bankhead; Jade Bryant; Bill Hoon Chang; Michael W Deininger; Monique L Den Boer; Brian J Druker; Guang Fan; William H Fleming; Luke B Fletcher; Jason M Glover; Jason R Gotlib; Tibor J Kovacsovics; Marc Loriaux
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.
Cancer research 2013;73(1):285-96.
2012: Vincent T Bicocca; Bill Hoon Chang; Brian J Druker; Marc Loriaux; Markus Muschen; Behzad Kharabi Masouleh; Jeffrey W Tyner
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.
Cancer cell 2012;22(5):656-67.
2012: Diederik van Bodegom; Oliver Weigert; Akinori Yoda; Jun Zhong; Liat Bird; Chaitali Dutta; Min-Sik Kim; Nadja Kopp; Akhilesh Pandey; Jeffrey W Tyner; David M Weinstock
Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.
Blood 2012;120(14):2853-63.
2012: Jinu Abraham; Jennifer Carew; Ying Xuan Chua; Brian J Druker; Francis J Giles; Jason M Glover; Aoife Kilcoyne; Marc Loriaux; Joel Michalek; Laura D Nelon; Yongjian Ouyang; Ranadip Pal; Brian P Rubin; Jeffrey W Tyner; Charles Keller
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.
Biochemical and biophysical research communications 2012;426(3):363-8.
2012: T Bains; Carol Beadling; Christopher L Corless; J Dunlap; Michael C Heinrich; Marc Loriaux; T L Neff; D Nelson; Jeffrey W Tyner; A Warrick; G Fan
Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
Leukemia 2012;26(9):2144-6.
2012: Jason M Glover; Marc Loriaux; Jeffrey W Tyner; Brian J Druker; Bill Hoon Chang
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Pediatric blood & cancer 2012;59(3):576-9.
2012: Jun Zhong; John Rush; Jyoti Sharma; Jeffrey W Tyner; David M Weinstock; Xinyan Wu; Akinori Yoda; Raghothama Chaerkady; Robert N Cole; Derese Getnet; Tai-Chung Huang; Min-Sik Kim; Marc M Loriaux; Christopher J Mitchell; Albrecht Moritz; Robert N O'Meally; Shyam M Palapetta; Akhilesh Pandey
TSLP signaling network revealed by SILAC-based phosphoproteomics.
Molecular & cellular proteomics : MCP 2012;11(6):M112.017764.
2012: Angela G Fleischman; Jeffrey W Tyner
JAK2 V617F down-modulates MPL.
Blood 2012;119(20):4579-80.
2012: Jeffrey W Tyner; Brian J Druker; A M Jemal; M Thayer; Bill Hoon Chang
Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.
Leukemia 2012;26(4):623-32.
2012: Anur Praveen; Enrico Cappelli; Carlo Dufour; Michael R Garbati; Laura E Hays; Winifred Keeble; Keaney R Rathbun; Johanna Svahn; Jeffrey W Tyner; Scott Vanderwerf; Jane Yates; Grover C Bagby
p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes.
Blood 2012;119(9):1992-2002.
2011: Jeffrey W Tyner
Phosphoproteomics microarray screen reveals novel interaction between MPL and Tensin2: implications for biology, disease and therapeutics.
Cell cycle (Georgetown, Tex.) 2011;10(16):2621-2.
2011: Christopher A Eide; Lauren T Adrian; Jeffrey W Tyner; Mary Mac Partlin; David J Anderson; Scott C Wise; Bryan D Smith; Peter A Petillo; Daniel L Flynn; Michael W N Deininger; Thomas O'Hare; Brian J Druker
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Cancer research 2011;71(9):3189-95.
2010: Jeffrey W Tyner; Luke B Fletcher; Ellen Q Wang; Wayne F Yang; Michael L Rutenberg-Schoenberg; Carol Beadling; Motomi Mori; Michael C Heinrich; Michael W N Deininger; Brian J Druker; Marc Loriaux
MET receptor sequence variants R970C and T992I lack transforming capacity.
Cancer research 2010;70(15):6233-7.
2009: Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Cancer cell 2009;16(5):401-12.
2009: Jeffrey W Tyner; Brian J Druker
RNAi screen for therapeutic target in leukemia.
Cell cycle (Georgetown, Tex.) 2009;8(14):2144.
2009: Jeffrey W Tyner; M L Rutenberg-Schoenberg; H Erickson; S G Willis; Thomas O'Hare; Michael W N Deininger; Brian J Druker; Marc Loriaux
Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.
Leukemia 2009;23(7):1345-8.
2009: Jeffrey W Tyner; Michael W N Deininger; Marc Loriaux; Bill Hoon Chang; Jason R Gotlib; Stephanie G Willis; Heidi Erickson; Tibor J Kovacsovics; Thomas O'Hare; Michael C Heinrich; Brian J Druker
RNAi screen for rapid therapeutic target identification in leukemia patients.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(21):8695-700.
2009: Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc Loriaux
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Blood 2009;113(8):1749-55.
2009: Jeffrey W Tyner; Marc Loriaux; H Erickson; C A Eide; J Deininger; Mary MacPartlin; S G Willis; Thoralf Lange; Brian J Druker; Tibor J Kovacsovics; Richard T Maziarz; N Gattermann; Michael W N Deininger
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia.
Leukemia 2009;23(2):406-9.
2008: Marc Loriaux; Ross Levine; Jeffrey W Tyner; Stefan Fröhling; Claudia Scholl; Eric P Stoffregen; Gerlinde Wernig; Heidi Erickson; Christopher A Eide; Roland Berger; Olivier A Bernard; James D Griffin; Richard M Stone; Benjamin Lee; Matthew Meyerson; Michael C Heinrich; Michael W N Deininger; D Gary Gilliland; Brian J Druker
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Blood 2008;111(9):4788-96.
2008: Thomas O'Hare; Christopher A Eide; Jeffrey W Tyner; Amie S Corbin; Matthew Wong; Sean Buchanan; Kevin Holme; Katayoun A Jessen; Crystal Tang; Hal A Lewis; Richard D Romero; Stephen K Burley; Michael W N Deininger
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(14):5507-12.
2008: Jeffrey W Tyner; Denise K Walters; Stephanie G Willis; Mary Luttropp; Jason Oost; Marc Loriaux; Heidi Erickson; Amie S Corbin; Thomas O'Hare; Michael C Heinrich; Michael W N Deininger; Brian J Druker
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.
Blood 2008;111(4):2238-45.
2008: C James Chou; Thomas O'Hare; Sophie Lefebvre; David Alvarez; Jeffrey W Tyner; Christopher A Eide; Brian J Druker; Joel M Gottesfeld
Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.
PloS one 2008;3(10):e3593.
2007: Ting-Lei Gu; Thomas Mercher; Jeffrey W Tyner; Valerie L Goss; Denise K Walters; Melanie G Cornejo; Cynthia Reeves; Lana Popova; Kimberly Lee; Michael C Heinrich; John Rush; Masanori Daibata; Isao Miyoshi; D Gary Gilliland; Brian J Druker; Roberto D Polakiewicz
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.
Blood 2007;110(1):323-33.
2006: Marcus Schittenhelm; Kevin W H Yee; Jeffrey W Tyner; Laura McGreevey; Andrea Haley; Ajia Town; Diana J Griffith; Troy Bainbridge; Rita M Braziel; Anne-Marie O'Farrell; Julie M Cherrington; Michael C Heinrich
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Leukemia 2006;20(11):2008-14.
2006: Denise K Walters; Thomas Mercher; Ting-Lei Gu; Thomas O'Hare; Jeffrey W Tyner; Marc Loriaux; Valerie L Goss; Kimberly A Lee; Christopher A Eide; Matthew Wong; Eric P Stoffregen; Laura McGreevey; Julie Nardone; Sandra A Moore; John Crispino; Titus Boggon; Michael C Heinrich; Michael W N Deininger; Roberto D Polakiewicz; D Gary Gilliland; Brian J Druker
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Cancer cell 2006;10(1):65-75.